Drug-Induced Psoriasis: 8 Common Culprit Drugs And How To Treat
Explore how medications can trigger or worsen psoriasis, including common culprits, clinical features, and effective management strategies.
Drug-induced psoriasis is a distinct form of psoriasis that develops or worsens due to exposure to specific medications. Unlike classic psoriasis, it often resolves upon discontinuation of the offending drug, though persistence can occur in some cases. This condition highlights the interplay between pharmacological agents and immune-mediated skin disorders, affecting patients without prior history or exacerbating existing disease.
What is Drug-Induced Psoriasis?
Drug-induced psoriasis refers to psoriatic lesions triggered by medications in individuals with no previous history of psoriasis, or exacerbation in those with pre-existing disease. It mimics plaque psoriasis morphologically but is causally linked to drug exposure. Discontinuation of the culprit drug typically leads to clearance, distinguishing it from idiopathic forms.
The pathophysiology involves drug-mediated immune dysregulation, often activating T-cell pathways similar to those in psoriasis vulgaris. Common in adults, it underscores the need for vigilance in polypharmacy settings.
Who Gets Drug-Induced Psoriasis?
Any individual can develop drug-induced psoriasis, particularly those on long-term medications for cardiovascular, psychiatric, or infectious conditions. Patients with a genetic predisposition (e.g., family history or HLA-B13, B17, B27) may be more susceptible. It occurs across ages but is frequently reported in adults over 40 using beta-blockers or lithium.
- Patients without prior psoriasis history: New-onset plaques post-drug initiation.
- Those with existing psoriasis: Rapid flares or resistance to prior therapies.
- High-risk groups: Elderly on antihypertensives, psychiatric patients on lithium.
Related or Overlapping Conditions
Drug-induced psoriasis overlaps with psoriasiform drug eruptions, which resemble psoriasis but lack histopathologic confirmation. Conditions like pityriasis rosea or lichenoid eruptions may mimic it. Paradoxical psoriasis from biologics (e.g., anti-TNF agents) presents similarly but involves treatment rebound.
| Condition | Key Features | Differentiator |
|---|---|---|
| Drug-Induced Psoriasis | Plaques, may resolve on withdrawal | Drug history, histopathology matches psoriasis |
| Psoriasiform Eruption | Scaly plaques, eczematous | No family history, faster resolution |
| Paradoxical Psoriasis | During anti-TNF therapy | Interferon-alpha mediated |
Clinical Features of Drug-Induced Psoriasis
Lesions typically appear 1-18 months after drug initiation, presenting as erythematous plaques with silvery scales on extensor surfaces, scalp, and nails. Pustular, erythrodermic, or palmoplantar variants occur, especially with antimalarials. Beta-blocker cases show psoriasiform dermatitis; lithium induces guttate forms.
Symptoms include itching, scaling, and joint pain in psoriatic arthritis overlaps. Nail pitting and onycholysis are common. In severe cases, erythroderma leads to systemic symptoms like fever and dehydration.
Drugs that Induce Psoriasis
Numerous drugs are implicated, with beta-blockers, lithium, and antimalarials most notorious. Others include interferons, NSAIDs, and biologics.
Beta-Blockers
Beta-blockers like propranolol and metoprolol provoke psoriasis in 4-11% of cases, often 1-18 months post-initiation. Psoriasiform eruptions predominate in non-psoriatic patients; existing disease worsens persistently until withdrawal.
Lithium
Lithium, used for bipolar disorder, exacerbates psoriasis in up to 50% of patients, with onset in weeks to months. Lesions may persist post-discontinuation but respond to inositol supplementation (6g daily).
Antimalarials
Chloroquine and hydroxychloroquine trigger pustular psoriasis (2-12 weeks latency), exacerbating 31-42% of cases. Avoid in predisposed individuals.
Other Common Culprits
- Interferons and Imiquimod: Induce plaque psoriasis via TLR7 activation.
- NSAIDs (e.g., naproxen): Short latency (1.6 weeks), propionic acid derivatives worst.
- Tetracyclines: 4% exacerbation rate; avoid in high-risk genotypes.
- Anti-TNF Biologics: Paradoxical psoriasis in 1-5%, managed by switching agents.
- VEGF Inhibitors (e.g., sorafenib): Rare paradoxical flares despite therapeutic potential.
Diagnosis of Drug-Induced Psoriasis
Diagnosis relies on temporal association (latency period), clinical morphology, and improvement post-withdrawal. Skin biopsy shows typical psoriatic features: parakeratosis, Munro microabscesses, dilated capillaries. Naranjo scale assesses probability.
Differential includes idiopathic psoriasis, contact dermatitis. Challenge-rechallenge (rarely ethical) confirms causality.
Management of Drug-Induced Psoriasis
First-line: Discontinue offending drug if feasible, replacing with alternatives (e.g., calcium channel blockers for beta-blockers). Lesions may persist, requiring psoriasis-standard therapies.
- Topical: Corticosteroids, vitamin D analogs (calcipotriol).
- Phototherapy: UVB, PUVA.
- Systemic: Methotrexate, acitretin, cyclosporine.
- Biologics: IL-17/IL-23 inhibitors for refractory cases; switch from anti-TNF if paradoxical.
For erythroderma: Fluid management, emollients. Lithium cases: Inositol adjunct.
Prevention of Drug-Induced Psoriasis
Screen high-risk patients (psoriasis history/family) before starting culprits. Use lowest effective doses, monitor skin monthly. Educate on early reporting of flares. Genetic testing (HLA) may guide avoidance.
Drug-Induced Psoriasis in Special Situations
- Pregnancy: Avoid teratogenic agents like acitretin; biologics case-by-case.
- Children: Imiquimod off-label use risks flares.
- Oncology: Balance VEGF inhibitor benefits vs. flares.
Frequently Asked Questions
What is the most common drug causing psoriasis flares?
Beta-blockers like propranolol are among the most frequent, affecting up to 11% of users.
Does drug-induced psoriasis go away after stopping the medication?
Often yes, within weeks to months, but persistence occurs in 20-50% requiring additional therapy.
Can biologics cause psoriasis?
Yes, anti-TNF agents induce paradoxical psoriasis in 1-5%; switch to IL inhibitors.
How is drug-induced psoriasis diagnosed?
By history, clinical exam, biopsy, and Naranjo score; resolution post-withdrawal confirms.
Are there alternatives to beta-blockers for hypertension in psoriasis patients?
Yes, ACE inhibitors or calcium channel blockers are safer options.
Outlook for Drug-Induced Psoriasis
Prognosis is excellent with prompt drug cessation; most clear fully. Refractory cases mimic chronic psoriasis but respond to escalated therapies. Early recognition prevents complications like erythroderma.
References
- Drug-Provoked Psoriasis: Is It Drug Induced or Drug Aggravated? Understanding Pathophysiology and Clinical Relevance — Journal of Clinical and Aesthetic Dermatology (JCAD). 2019-01-01. https://jcadonline.com/drug-provoked-psoriasis-is-it-drug-induced-or-drug-aggravated-understanding-pathophysiology-and-clinical-relevance/
- Drug-induced psoriasis: clinical perspectives — PMC – NIH (PubMed Central). 2017-12-20. https://pmc.ncbi.nlm.nih.gov/articles/PMC5774610/
- What drugs can cause psoriasis? List and what to do — Medical News Today. 2023-05-15. https://www.medicalnewstoday.com/articles/what-drugs-can-cause-psoriasis
- Drug Induced Psoriasis — Acta Dermatovenerologica Croatica. 2011-12-01. https://actadermatovenerologicacroatica.hr/wp-content/uploads/2022/11/ADC-2011-648.pdf
- Drug-induced psoriasis — DermNet NZ. 2023-01-01. https://dermnetnz.org/topics/drug-induced-psoriasis
Similar Articles
Read full bio of Sneha Tete
